Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Pre-eclampsia
In brief
This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with pre-eclampsia.
Key facts
- Study ID
- NCT01566630
- Run by
- Novartis Pharmaceuticals
- People needed
- 3
- Starts
- 2013-05-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2015-11-05
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Mobile, Alabama, United States
- Novartis Investigative Site — Lexington, Kentucky, United States
- Novartis Investigative Site — Louisville, Kentucky, United States
- Novartis Investigative Site — Galveston, Texas, United States
- Novartis Investigative Site — Modena, MO, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.